Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The randomized clinical phase III trial, identified as NCT01104935 (RESPECT), demonstrated that trastuzumab monotherapy did not achieve its primary goal of noninferiority. Despite this, the reduction in survival without chemotherapy was only 1 month at the 3-year mark. Consequently, given its lower toxicity and more favorable health-related quality of life (HRQoL) profile, trastuzumab monotherapy may be considered a viable adjuvant therapy option for certain older patients.
The results of the randomized clinical phase III trial NCT00712140 indicate that a 6-month course of trastuzumab is just as effective as a 12-month course for patients with [Breast Cancer / Mammacarcinoma (HER2+)](brain://AM4HkG7CREak0Y5bQ1ejlg/BreastCanc…